c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3
- PMID: 20150913
- DOI: 10.1038/cdd.2010.8
c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3
Abstract
Galectin-3 (Gal3) has important roles in tumor transformation and metastasis. This study shows that c-Abl and Abl-related gene (Arg) associate with and phosphorylate Gal3. The SH (Src homology)3 domains of c-Abl/Arg bind to a P(80)GPPSGP motif of Gal3, and Tyr79 and Tyr118 are the major tyrosine phosphorylation sites. A consequence of this interaction and phosphorylation is the significant impairment of chaperone-mediated autophagy of Gal3. Cells expressing Gal3 and treated with the c-Abl/Arg inhibitor STI571, Gal3-depleted cells, and Gal3-depleted cells expressing Gal3 phosphorylation mutants all display an increased sensitivity to apoptosis-inducing agents. In addition, tumor cells expressing the phosphorylation mutants show impaired tumorigenicity. These results partially explain the antiapoptotic effect of Abl and Arg. As tumors frequently overexpress Gal3, a c-Abl/Arg-specific inhibitor may potentially be applied along with other antitumor drugs to target the lysosomal degradation of Gal3 in tumor therapy.
Similar articles
-
Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates proteasome degradation.Mol Cell. 2006 May 5;22(3):317-27. doi: 10.1016/j.molcel.2006.04.007. Mol Cell. 2006. PMID: 16678104
-
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21. Oncogene. 2008. PMID: 18427551
-
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.Cancer Res. 2003 Jan 15;63(2):375-81. Cancer Res. 2003. PMID: 12543790
-
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].Orv Hetil. 2002 Oct 20;143(42):2379-84. Orv Hetil. 2002. PMID: 12440260 Review. Hungarian.
-
Galectin-3 in metabolic disorders: mechanisms and therapeutic potential.Trends Mol Med. 2025 May;31(5):424-437. doi: 10.1016/j.molmed.2024.11.006. Epub 2024 Dec 16. Trends Mol Med. 2025. PMID: 39690058 Review.
Cited by
-
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17468-73. doi: 10.1073/pnas.1111138108. Epub 2011 Oct 10. Proc Natl Acad Sci U S A. 2011. PMID: 21987825 Free PMC article.
-
Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage.J Biol Chem. 2012 Feb 17;287(8):5192-8. doi: 10.1074/jbc.C111.331686. Epub 2012 Jan 9. J Biol Chem. 2012. PMID: 22232548 Free PMC article.
-
Targeting Chaperone-Mediated Autophagy for Disease Therapy.Curr Pharmacol Rep. 2018 Jun;4(3):261-275. doi: 10.1007/s40495-018-0138-1. Epub 2018 May 2. Curr Pharmacol Rep. 2018. PMID: 34540559 Free PMC article.
-
Role of c-Abl in L-selectin shedding from the neutrophil surface.Blood Cells Mol Dis. 2011 Mar 15;46(3):246-51. doi: 10.1016/j.bcmd.2010.12.010. Epub 2011 Feb 1. Blood Cells Mol Dis. 2011. PMID: 21277237 Free PMC article.
-
Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade.Cell Commun Signal. 2021 May 22;19(1):59. doi: 10.1186/s12964-021-00739-6. Cell Commun Signal. 2021. PMID: 34022881 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous